Detalhe da pesquisa
1.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34246347
2.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34860318
3.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34264439
4.
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 39(1): 163-174, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32737717
5.
Robust network inference using response logic.
Bioinformatics
; 35(14): i634-i642, 2019 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31510692
6.
bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays.
Bioinformatics
; 35(8): 1350-1357, 2019 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30215668
7.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 419-432, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31020608
8.
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Br J Cancer
; 121(7): 522-528, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31417188
9.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Lancet Oncol
; 19(3): 310-322, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29449192
10.
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Nat Chem Biol
; 12(7): 531-8, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27214401
11.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 18(10): 1360-1372, 2017 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28800861
12.
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 17(9): 1248-60, 2016 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-27480103
13.
Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS.
Lancet Oncol
; 18(11): e638, 2017 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29208392
14.
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.
Nat Commun
; 14(1): 5945, 2023 09 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37741832
15.
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Clin Cancer Res
; 28(5): 993-1003, 2022 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34907082
16.
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Clin Cancer Res
; 27(4): 1162-1173, 2021 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33023953
17.
Tumour gene expression signature in primary melanoma predicts long-term outcomes.
Nat Commun
; 12(1): 1137, 2021 02 18.
Artigo
Inglês
| MEDLINE | ID: mdl-33602918
18.
Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer.
JCO Precis Oncol
; 4: 1012-1024, 2020 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35050767
19.
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
Clin Cancer Res
; 26(1): 46-53, 2020 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31732523
20.
The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs.
Life Sci Alliance
; 2(4)2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31253656